AstraZeneca to buy Alexion for $39bn

AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Indian court rejects AstraZeneca’s injunction request

24 November 2020 The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.

Americas

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

18 November 2020 Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

More features

Brazil’s patent shakeup: How pharma is handling a new reality

Eli Lilly strikes AI drug discovery deal with US biotech

Why AI drug discovery has an IP problem and what can be done

Blank Rome adds more patent attorneys in ‘strategic expansion’

Simmons & Simmons patent litigator jumps ship

ITC probes on the rise, but gender parity lags behind

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

AstraZeneca to buy Alexion for $39bn

More on this story

Editor's picks

Editor's picks

More features